Knowledge centre

New EU HTA Regulations: Why It Matters to You and How Phastar Can Help You Be Prepared

1 minute read

Published: June 14th, 2024

EU HTA regulations are changing the way we conduct HTA submissions with EU regulators. Prior to the introduction of this legislation, submission to each member state’s regulatory body could be done in a staggered approach. This won’t be the case with EUnetHTA.

Read our latest article on the impact of these changes and how Phastar can help you be prepared.

Related articles

Leveraging Real-World Data for in-silico Trials: Enhancing Clinical Development and Regulatory Confidence

Leveraging Real-World Data for in-silico Trials: Enhancing Clinical Development and Regulatory Confidence

December 3rd, 2025 1 minute read

As the pharmaceutical landscape evolves, traditional clinical trial designs are increasingly complemented by innovati...

Advancing Clinical Trial Design with Bayesian Statistics and Prior Elicitation

Advancing Clinical Trial Design with Bayesian Statistics and Prior Elicitation

April 1st, 2025 1 minute read

Discover how Bayesian statistics can enhance clinical trial efficiency and improve decision-making. Our latest white ...

Unlock the Power of Real-World Evidence in Clinical Research

Unlock the Power of Real-World Evidence in Clinical Research

February 25th, 2025 1 minute read

Discover how Real-World Evidence (RWE) is revolutionizing drug development and clinical decision-making in our latest...